The Cardiovascular Effects of the Glucagon-Like-Peptide-1 Receptor Agonist Liraglutide in Patients with Coronary Artery Disease and Newly Diagnosed Type 2 Diabetes - A randomized double-blind placebo-controlled crossover study (the AddHope2 study)

Premavathanan Muthukumarapillai

The Cardiovascular Effects of the Glucagon-Like-Peptide-1 Receptor Agonist Liraglutide in Patients with Coronary Artery Disease and Newly Diagnosed Type 2 Diabetes - A randomized double-blind placebo-controlled crossover study (the AddHope2 study)

Premavathanan Muthukumarapillai

Morphogenesis and Differentiation Program

Originalsprog	Engelsk

Status	Udgivet - 3 feb. 2017

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Citationsformater

@phdthesis{7aafefd76eb14963b7eddb2f053ccb46,

title = "The Cardiovascular Effects of the Glucagon-Like-Peptide-1 Receptor Agonist Liraglutide in Patients with Coronary Artery Disease and Newly Diagnosed Type 2 Diabetes - A randomized double-blind placebo-controlled crossover study (the AddHope2 study)",

author = "Premavathanan Muthukumarapillai",

year = "2017",

month = feb,

day = "3",

language = "English",

}

TY - BOOK

T1 - The Cardiovascular Effects of the Glucagon-Like-Peptide-1 Receptor Agonist Liraglutide in Patients with Coronary Artery Disease and Newly Diagnosed Type 2 Diabetes - A randomized double-blind placebo-controlled crossover study (the AddHope2 study)

AU - Muthukumarapillai, Premavathanan

PY - 2017/2/3

Y1 - 2017/2/3

M3 - Ph.D. thesis

BT - The Cardiovascular Effects of the Glucagon-Like-Peptide-1 Receptor Agonist Liraglutide in Patients with Coronary Artery Disease and Newly Diagnosed Type 2 Diabetes - A randomized double-blind placebo-controlled crossover study (the AddHope2 study)

ER -